Predict your next investment

Private Equity
FINANCE | Investment Firms & Funds
dukestreet.com

See what CB Insights has to offer

Investments

11

Portfolio Exits

19

Funds

16

Partners & Customers

1

About Duke Street

Duke Street is a private equity firm that invests in Western European mid-market companies across five sectors: Consumer, Business Services, Healthcare, Financial Services, and Industrial & Engineering.

Duke Street Headquarter Location

Nations House 103 Wigmore Street

London, England, W1U 1QS,

United Kingdom

+44 (0)20 7663 8500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Duke Street Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Duke Street Rank

Latest Duke Street News

Duke Street Bio enters stage with next-generation cancer therapies

May 25, 2022

25/05/2022 - 3 minutes The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline into clinical studies. The company aims to deliver next-generation cancer therapies based on DNA damage repair (DDR) and immuno-oncology and claims to have made rapid development progress. It has several drug discovery programs targeting the key enzymes that control DDR and immune system activation. Poly (ADP-ribose) polymerases, or PARPs, are a type of enzyme that helps repair DNA damage in cells. PARP inhibitors work by preventing cancer cells from carrying out vital DNA repairs inside the cell. Duke Street Bio was founded in 2020 by the management team behind the Scottish firm IOmet Pharma. IOmet Pharma, which developed medicines for cancer with a focus on immunotherapy and metabolism, went on to be bought by US-based MSD in 2016. “We focused on immuno-oncology at IOmet and it made sense to continue that with Duke Street,” Alan Wise, Duke Street Bio chief executive and co-founder, told us. Related Content “And then we’ve got involved in the DNA damage repair space as well. There’s a lot of connectivity between DDR and immuno-oncology. There’s a lot of emerging evidence to show that deficiencies or genetic vulnerabilities in DDR can impact very positively on orchestrating an immune response.” While marketed DDR and immuno-oncology therapies only work in limited patient populations, the molecules Duke Street Bio is developing could significantly expand the number of patients that could benefit from these types of treatment approaches, he said. The startup’s DDR program targets PARP1, an enzyme that’s essential for initiating various forms for DNA repair and which has been clinically verified. The company says its second-generation approach means it can deliver safer therapeutics that can be used in combination with chemotherapies and targeted agents. The immuno-oncology program targets PARP7, an enzyme that has recently emerged as a key regulator of the immune system in the tumor microenvironment. Inhibitors of PARP7 can create a hostile immune environment to the cancer that enables tumor targeting and elimination. Duke Street Bio’s goal is to reprogram the cancer cell and tumor microenvironment biology to harness the natural power of the body’s immune system to fight cancer. “There is significant therapeutic opportunity in further exploration of the cellular signaling pathways controlled by the PARP family of enzymes,” said Elliott Sigal, advisor to Duke Street Bio and former chief scientific officer and president of research and development at Bristol Myers Squibb. Related Content Additional programs focused on related enzymes are at the validation phase, the company said. The startup has a similar hybrid business model to that of IOmet Pharma, with a small internal team and the outsourcing of experimental work to contract research organizations around the world, some of which the team has worked with for over a decade. “We’ve got the track record so fundraising has been relatively straightforward,” Peter Trill, chairman and co-founder of Duke Street Bio, told us. Other companies researching cancer therapies based on DNA repair include Artios, which is developing DNA damage response inhibitors and raised €129M in a Series C funding round last year. Breakpoint Therapeutics , a spinoff from German biotech Evotec, aims to develop drugs that kill cancer cells by sabotaging their DNA repair machinery. Meanwhile, Paris-based Onxeo is trialing a cancer treatment that interferes with DNA repair mechanisms. Cover image via Shutterstock

Duke Street Investments

11 Investments

Duke Street has made 11 investments. Their latest investment was in Parabis Group as part of their Private Equity - II on December 12, 2014.

CBI Logo

Duke Street Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/5/2014

Private Equity - II

Parabis Group

$20.27M

No

1

2/6/2012

Private Equity

Parabis Group

Yes

1

4/15/2010

Growth Equity

Oasis Healthcare

$45.82M

Yes

Undisclosed Investors

1

1/31/2004

Private Equity

Subscribe to see more

Subscribe to see more

10

8/7/2000

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/5/2014

2/6/2012

4/15/2010

1/31/2004

8/7/2000

Round

Private Equity - II

Private Equity

Growth Equity

Private Equity

Private Equity

Company

Parabis Group

Parabis Group

Oasis Healthcare

Subscribe to see more

Subscribe to see more

Amount

$20.27M

$45.82M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors

Sources

1

1

1

10

10

Duke Street Portfolio Exits

19 Portfolio Exits

Duke Street has 19 portfolio exits. Their latest portfolio exit was Voyage Care on January 14, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/14/2022

Acquired

4

4/8/2019

Merger

1

12/13/2017

Acquired

3

5/23/2017

Acq - Fin - II

Subscribe to see more

Subscribe to see more

10

11/11/2015

Acquired

Subscribe to see more

Subscribe to see more

10

Date

1/14/2022

4/8/2019

12/13/2017

5/23/2017

11/11/2015

Exit

Acquired

Merger

Acquired

Acq - Fin - II

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

1

3

10

10

Duke Street Acquisitions

40 Acquisitions

Duke Street acquired 40 companies. Their latest acquisition was COMPO - Consumer Business on June 05, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/5/2021

$99M

Acquired Unit - Fin

2

6/3/2021

$99M

Acq - Fin

4

6/3/2021

$99M

Acq - Fin - II

2

6/3/2019

Subscribe to see more

$99M

Subscribe to see more

10

6/3/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/5/2021

6/3/2021

6/3/2021

6/3/2019

6/3/2019

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired Unit - Fin

Acq - Fin

Acq - Fin - II

Subscribe to see more

Subscribe to see more

Sources

2

4

2

10

10

Duke Street Fund History

16 Fund Histories

Duke Street has 16 funds, including Duke Street Fund VI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2007

Duke Street Fund VI

1

6/28/2007

DSC VI

Diversified Private Equity

Closed

$1,154.02M

1

8/2/2004

Duchess III

Diversified Private Equity

Closed

$548.96M

1

4/25/2003

Duchess II

Subscribe to see more

Subscribe to see more

$99M

10

6/1/2002

DSC V LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2007

6/28/2007

8/2/2004

4/25/2003

6/1/2002

Fund

Duke Street Fund VI

DSC VI

Duchess III

Duchess II

DSC V LP

Fund Type

Diversified Private Equity

Diversified Private Equity

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$1,154.02M

$548.96M

$99M

$99M

Sources

1

1

1

10

10

Duke Street Partners & Customers

1 Partners and customers

Duke Street has 1 strategic partners and customers. Duke Street recently partnered with Goldman Sachs, and Arcano Capital on March 3, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

3/31/2016

Partner

United States, and Spain

Duke Street teams up with Goldman Sachs and Arcano to restructure Fund VI - Duke Street

• Peter Taylor , managing partner , joined Duke Street in 1996 after qualifying as a chartered accountant and working at Bridgepoint .

2

Date

3/31/2016

Type

Partner

Business Partner

Country

United States, and Spain

News Snippet

Duke Street teams up with Goldman Sachs and Arcano to restructure Fund VI - Duke Street

• Peter Taylor , managing partner , joined Duke Street in 1996 after qualifying as a chartered accountant and working at Bridgepoint .

Sources

2

Duke Street Team

6 Team Members

Duke Street has 6 team members, including former Chief Executive Officer, Ian Hazelton.

Name

Work History

Title

Status

Ian Hazelton

Royal Bank of Scotland

Chief Executive Officer

Former

Edmund Truell

Chief Executive Officer

Former

Frederic Chauffier

Managing Director

Former

Graham Lee

Managing Director

Former

Ervin Schellenberg

Managing Director

Former

Name

Ian Hazelton

Edmund Truell

Frederic Chauffier

Graham Lee

Ervin Schellenberg

Work History

Royal Bank of Scotland

Title

Chief Executive Officer

Chief Executive Officer

Managing Director

Managing Director

Managing Director

Status

Former

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.